Newway Pharmaceutical

Newway Pharmaceutical is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the discovery and development of small molecule therapeutics for central nervous system (CNS) and inflammatory disorders. Founded in 2017 by industry veterans with significant experience at global pharmaceutical firms like Teva and Novartis, the company focuses on high-potential targets such as PDE4 and specific ion channels. Newway's pipeline includes candidates for dermatological conditions like atopic dermatitis and psoriasis, as well as treatments for neuropathic pain and chronic cough. The company has successfully raised significant capital from top-tier investors like Lilly Asia Ventures and Sequoia China to advance its proprietary drug discovery platform and clinical-stage assets. Newway operates R&D centers in both Suzhou and Shenzhen to leverage regional talent in medicinal chemistry and neurobiology.